Therapeutic potential of Sulphasalazine to reduce ultrasonography detected synovitis.
Phase 2
- Conditions
- Health Condition 1: M179- Osteoarthritis of knee, unspecified
- Registration Number
- CTRI/2024/02/062916
- Lead Sponsor
- I
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient in chronic knee pain(pain more than 3 months) diagnosed as OA Knee of either grade I,II or III in accordance to kellgren Lawrence(KL) grading system 45 TO 80 years age, having ultrasound features of synovial hypertrophy will be included in our study.
Exclusion Criteria
Patients coexistent local or systemic inflammatory processes, OA knee grade (IV) history of inflammatory arthropathies or knee joint surgery, patients with hypersensitivity to sulfasalazine, its metabolite, sulfonamides, salicylates, or any component of the formulation, intestinal or urinary obstruction, and porphyria, will also be excluded from the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoints of the study will be effusion-synovitis volume and VAS painTimepoint: 6 and 12 weeks
- Secondary Outcome Measures
Name Time Method 1) Total dosage of analgesic requirement. <br/ ><br>2) Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) <br/ ><br>Timepoint: 6 and 12 weeks